UBS AM
CRBU icon

UBS AM’s Caribou Biosciences CRBU Stock Holding History

UBS AM’s Portfolio CRBU Stock Details CRBU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-12,195
Closed -$23.9K – 2671
2024
Q3 		$23.9K Hold
12,195
– – ﹤0.01% 2794
2024
Q2 		$20K Buy
+12,195
New +$39K ﹤0.01% 2789
2023
Q3 		– Sell
-32,062
Closed -$170K – 2614
2023
Q2 		$170K Hold
32,062
– – ﹤0.01% 2590
2023
Q1 		$170K Sell
32,062
-29,300
-48% -$182K ﹤0.01% 2590
2022
Q4 		$385K Buy
61,362
+1,298
+2% +$11.5K ﹤0.01% 2274
2022
Q3 		$634K Sell
60,064
-1,954
-3% -$18.2K ﹤0.01% 2232
2022
Q2 		$337K Buy
62,018
+31,718
+105% +$242K ﹤0.01% 2438
2022
Q1 		$278K Buy
+30,300
New +$319K ﹤0.01% 2614

Other funds holding CRBU

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
EWM
Elmwood Wealth Management Berkeley, California $400M AUM 17.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS AM's CRBU Position: Q4 2024 in Review

UBS AM sold out of Caribou Biosciences (CRBU) in Q4 2024, closing a stake of 12,195 shares — an estimated $23.9K sold.

UBS AM first reported a position in CRBU in Q1 2022 and held it in 8 quarters. The position peaked at $634K in Q3 2022. 133 funds tracked by Wall St. Rank hold CRBU as of Q4 2024.

  • UBS AM reported no remaining Caribou Biosciences position as of Q4 2024 after selling out during the quarter.
  • UBS AM sold 12,195 Caribou Biosciences shares in Q4 2024, an estimated $23.9K.
  • UBS AM first reported a position in Caribou Biosciences in Q1 2022 and held it in 8 quarters.
  • UBS AM's Caribou Biosciences position peaked at $634K in Q3 2022.
  • 133 funds tracked by Wall St. Rank held Caribou Biosciences as of Q4 2024.

Based on UBS AM's 13F filing for Q4 2024, filed 14 Feb 2025.